Weight-Loss Drug Stocks Surge as Boji Pharma Hits 20% Daily Limit on Contract with Nuotai Bio

Stock trading depends onGolden Qilin Analyst Report, authoritative, professional, timely, comprehensive, help you explore potential theme opportunities!

Institutions pointed out that in recent years, the sales scale of GLP-1 polypeptide drugs in the Chinese market has rapidly expanded, with an estimated total sales of 6 billion yuan in 2022.

On February 20, the weight-loss drug concept stocks saw significant gains, as of press time.BojiMed20% price limit up,Hebei Changshan Biochemical Pharmaceutical Co., Ltd.Up more than 16%,Kingchem (Liaoning) Life Science Co., Ltd.Up more than 14%,Gan&Lee Pharmaceuticals、Hybio Pharmaceutical、Sinopep、Suzhou Highfine Biotech Co.,ltd.Wait for the high.

News update: Boji Medical Technology Co., Ltd. announced last night that it had signed a "Technical Service (Entrustment) Contract" with Sinopep Allsino Bio Pharmaceutical Co., Ltd., with a total contract value of 110 million yuan (including tax). The contract stipulates that Sinopep Allsino Bio will entrust BojiMed to provide clinical research services for "Semaglutide Injection."

On February 5, Danish pharmaceutical giant Novo Nordisk announced the expansion of its "weight-loss wonder drug" production. Its major shareholder, Novo Holdings, declared the acquisition of Catalent, a U.S.-based biopharmaceutical contract manufacturer. Novo Nordisk will acquire three filling plants from Novo Holdings for an upfront payment of $11 billion.

In terms of performance, Novo Nordisk's 2023 annual financial report shows that driven by anti-obesity and diabetes drugs, Novo Nordisk achieved strong growth. The total annual revenue reached 232.261 billion Danish kroner (approximately 33.771 billion US dollars), increasing by 31% year-on-year; the profit was 102.574 billion Danish kroner (approximately 14.914 billion US dollars), growing by 37% year-on-year.

SDIC Securities pointed out that the weight loss indications of Novo Nordisk's Semaglutide and Innovent's Mastydopeptide have entered the NDA stage. It is expected that after the weight loss indications of Eli Lilly's Tirzepatide, Novo Nordisk's Semaglutide, and Innovent's Mastydopeptide are marketed, the scale of the GLP-1 drug market will further expand.

　　Founder SecuritiesIt is also believed that the rapid expansion of the weight-loss market will further open up the global market for semaglutide. The potential applications of GLP-1 therapy in health issues continue to be highly promising, and the domestic industry chain in China is expected to experience rapid growth in the future.

Editor: Yang Hongyan